Abstract:Abstract CRSIPR-Cas9 system has opened up the avenue to efficient genome editing 1–4 . However, together with known off-target effects, several concerns of current CRISPR-Cas9 platform, including severe DNA damage, cytotoxicity, and large genomic alteration, have emerged in recent reports 5–7 and establish a formidable obstacle to precisely model allele dosage effects of disease mutations and risk variants, especially mono-allelic effects, and correct them. Here, by developing an allele-specific indel monitor system (AIMS), we demonstrate that small and simple modification of conventional single-guide RNAs (sgRNAs) enable programmable tuning of CRISPR-Cas9 activities and alleviate such adverse effects. AIMS, which visualizes various indel events in two alleles separately in living cells, is convenient and accurate to determine the in vitro editing efficiency and revealed frequent mosaicism during genome editing. Using AIMS, we show that adding cytosine stretches to the 5’ end of conventional sgRNA efficiently reduced Cas9 activity in a length dependent manner. By combining systematic experiments and computational modeling, we established the quantitative relationships between the length of cytosine extension and multiple aspects of CRISPR-Cas9 system. In general, short cytosine extension dramatically relieves p53-dependent cytotoxicity and suppression of homology-directed repair (HDR) while relatively maintaining on-target activity. Long cytosine extension further decreases on-target activity, thereby maximizing mono-allelic editing, while conventional system typically induces bi-allelic editing. Furthermore, such downregulation of on-target activity contributes to downregulation of relative off-target activity and protection of HDR-allele from second off-target editing. Therefore, cytosine extension method finally enables both single-step generation of heterozygous single-nucleotide disease mutations from homozygous states in mouse ES cells and correction of heterozygous disease mutations in human iPS cells. Taken together, our study proposes updates of standard CRISPR-Cas9 platform in mammalian cells toward precise and safe genome editing in diverse applications.

Hairpin‐Spacer crRNA‐Enhanced CRISPR/Cas13a System Promotes the Specificity of Single Nucleotide Polymorphism (SNP) Identification

High-Fidelity DNAzyme-Assisted CRISPR/Cas13a System with Single-Nucleotide Resolved Specificity

Iterative crRNA design and a PAM-free strategy enabled an ultra-specific RPA-CRISPR/Cas12a detection platform

Harnessing noncanonical trans -cleavage characteristics of Cas12 and Cas13a to enhance CRISPR-based diagnostics

Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family

Binding-driven forward tearing protospacer activated CRISPR-Cas12a system and applications for microRNA detection

DNA-guided CRISPR/Cas12 for RNA targeting

High-Fidelity Identification of Single Nucleotide Polymorphism by Type V CRISPR Systems

Massively parallel profiling of RNA-targeting CRISPR-Cas13d

High-fidelity detection of DNA combining the CRISPR/Cas9 system and hairpin probe

Deleting Specific Residues From the HNH Linkers Creates A CRISPR-SpCas9 Variant With High Fidelity and Efficiency

Precise amplification-free detection of highly structured RNA with an enhanced SCas12a assay

Discovery and engineering of ChCas12b for precise genome editing

Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications

High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.

Screening DNA Aptamers That Control the DNA Cleavage, Homology-Directed Repair, and Transcriptional Regulation of the CRISPR-(d)Cas9 System.

A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing

HideRNAs protect against CRISPR-Cas9 re-cutting after successful single base-pair gene editing

CRISPR-Cas13a system: A novel tool for molecular diagnostics

Programmable downsizing of CRISPR-Cas9 activity for precise and safe genome editing

Programmable RNA targeting with the single-protein CRISPR effector Cas7-11